NUCLIDIUM AG successfully raised €84 million in a Series B financing round to advance its innovative copper-based radiopharmaceutical platform targeting oncology applications.

Information on the Target

NUCLIDIUM AG is a Switzerland-based clinical-stage biotechnology company that is at the forefront of developing innovative copper-based radiopharmaceuticals for cancer diagnosis and treatment. The company's proprietary platform utilizes Copper-61 for diagnostic purposes and Copper-67 for therapeutic applications, addressing significant challenges currently faced in the field of radiotheranostics. Through this technology, NUCLIDIUM aims to enhance clinical efficacy and streamline manufacturing processes, providing impactful radiopharmaceutical solutions worldwide.

Recently, NUCLIDIUM announced the successful completion of a Series B financing round, raising CHF 79 million (approximately EUR 84 million). These funds will support the clinical advancement of their pipeline, which includes focused efforts on oncology applications such as metastatic prostate cancer and neuroendocrine tumors. The company's research demonstrates promising results, with initial clinical data suggesting improved diagnostic capabilities and safety compared to existing imaging methods.

Industry Overview in Switzerland

Switzerland is recognized as a global hub for life sciences and biotechnology, characterized by a robust ecosystem of research institutions, innovative companies, and skilled talent. The biopharmaceutical market in Switzerland is one of the largest in Europe, contributing signifi